Filing Flows › Usana Health Sciences (USNA) › Q3 2025
Usana Health Sciences (USNA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Usana Health Sciences (USNA) reported revenue of $214M for the third quarter 2025 (Q3 2025), +7% from a year earlier and -9% from the quarter before. Operating margin was 0.6%, net loss $6.7M (3.1% of revenue).
Usana Health Sciences, Q3 2025: revenue $214M (+7% year over year), operating margin 0.6%, net loss $6.7M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $214M | -9% | +7% |
| Operating profit | $1.2M | -93% | — |
| Net earnings | −$6.7M | -169% | — |
| Operating cash flow | −$2.0M | -116% | — |
What changed
Revenue was $213.7M in Q3 2025, up 7% year over year and down 9% from the previous quarter.
Gross margin was 77.2%, down 3.2 points from a year earlier. Operating profit was $1.2M, a 0.6% margin (down 7.2 points year over year). Operating profit fell $14.4M even though revenue rose $13.4M versus a year earlier, so costs grew faster than sales. Operating expenses grew 13% against revenue growth of 7%. The fastest-growing cost line was SG&A (+40%). The quarter ended with a net loss of $6.7M, after a profit of $10.4M the previous quarter. Non-operating items added $570K, 32% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.0M. Non-cash charges added back $7.9M of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items used $6.8M. Capital expenditures of $3.2M exceeded it, leaving free cash flow of −$5.2M.
Questions
What was Usana Health Sciences' revenue in the third quarter 2025?
Usana Health Sciences (USNA) reported revenue of $214M for the third quarter 2025 (Q3 2025), +7% from a year earlier and -9% from the quarter before.
Was Usana Health Sciences profitable in the third quarter 2025?
Operating profit was $1.2M (0.6% of revenue) and net loss $6.7M.